·Single test for SARS-CoV-2, influenza A, and influenza B—detect and differentiate between disease states with similar clinical symptoms, and get the information needed to help monitor the spread of COVID-19 and the flu
·Affordable and scalable—add to your existing COVID-19 testing menu andinfrastructure to expand your respiratory sample testing while maintaining lowoperational costs and workflow simplicity
·Multitarget assay design—helps compensate for emerging SARS-CoV-2 variants and mutations to help provide confidence in results
Product performance index
·Detection limit: the detection limit is not less than 5.0 × 10² copies / mL.
·Negative coincidence rate: Seven enterprise negative reference materials N1-N7 (human cytomegalo virus, rotavirus, respiratory syncytial virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptoco ccus pneumoniae and Staphylococcus aureus) were tested. There was no cross reaction, and the nega tive coincidence rate was 100%.
·Precision:the CV of FAM, VIC/HEX and ROX channel Ct values was no more than 5.0% after 10 times of repeated testing.
·Positive coincidence rate: 7 enterprise positive reference materials P1-P7 were tested, and the positive coincidence rate was 100%.